Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

934 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study.
Schröder FH, Kurth KH, Fosså SD, Hoekstra W, Karthaus PP, Debois M, Collette L; Members of the European Organisation for the Research and Treatment of Cancer Genito-urinary Group. Schröder FH, et al. Among authors: fossa sd. J Urol. 2004 Sep;172(3):923-7. doi: 10.1097/01.ju.0000135742.13171.d2. J Urol. 2004. PMID: 15310999 Clinical Trial.
Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial).
Schröder FH, Kurth KH, Fossa SD, Hoekstra W, Karthaus PP, De Prijck L, Collette L. Schröder FH, et al. Among authors: fossa sd. Eur Urol. 2009 Jan;55(1):14-22. doi: 10.1016/j.eururo.2008.09.008. Epub 2008 Sep 17. Eur Urol. 2009. PMID: 18823693 Clinical Trial.
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R. Fitzpatrick JM, et al. Eur J Cancer. 2014 Jun;50(9):1617-27. doi: 10.1016/j.ejca.2014.03.010. Epub 2014 Apr 3. Eur J Cancer. 2014. PMID: 24703899 Free article.
Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7.
Fosså SD, Wiklund F, Klepp O, Angelsen A, Solberg A, Damber JE, Hoyer M, Widmark A; The Scandinavian Prostate Cancer Group-7 Investigators. Fosså SD, et al. Eur Urol. 2016 Oct;70(4):684-691. doi: 10.1016/j.eururo.2016.03.021. Epub 2016 Mar 26. Eur Urol. 2016. PMID: 27025586 Clinical Trial.
Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium.
Bjerner J, Bratt O, Aas K, Albertsen PC, Fosså SD, Kvåle R, Lilja H, Müller C, Müller S, Stensvold A, Thomas O, Røe OD, Vickers A, Walz J, Carlsson SV, Oldenburg J. Bjerner J, et al. Among authors: fossa sd. Eur Urol. 2023 May 9:S0302-2838(23)02791-4. doi: 10.1016/j.eururo.2023.04.028. Online ahead of print. Eur Urol. 2023. PMID: 37169639
934 results